ADMA Biologics Newsroom

Mizuho Securities Maintains ADMA Biologics(ADMA.US) With Buy Rating, Announces Target Price $28

Moomoo NewsDec 17 12:32 ET

Mizuho Securities Maintains ADMA Biologics(ADMA.US) With Buy Rating

Moomoo NewsDec 3 02:32 ET

Mizuho Securities Maintains ADMA Biologics(ADMA.US) With Buy Rating, Maintains Target Price $24

Moomoo NewsNov 20 07:34 ET

Mizuho Securities Maintains ADMA Biologics(ADMA.US) With Buy Rating, Announces Target Price $24

Moomoo NewsNov 8 20:31 ET

ADMA Biologics Is Maintained at Strong Buy by Raymond James

Dow JonesNov 8 12:46 ET

ADMA Biologics Analyst Ratings

BenzingaNov 8 12:37 ET

H.C. Wainwright Maintains ADMA Biologics(ADMA.US) With Buy Rating, Raises Target Price to $26

Moomoo NewsNov 8 07:31 ET

Key Takeaways From ADMA Biologics Analyst Ratings

BenzingaOct 14 08:02 ET

H.C. Wainwright Maintains ADMA Biologics(ADMA.US) With Buy Rating, Maintains Target Price $18

Moomoo NewsOct 14 06:31 ET

Maintaining Buy Rating on ADMA Biologics Amid Auditor Resignation: Confidence in Fiscal Health and Compliance

TipRanksOct 14 06:17 ET

ADMA Biologics (ADMA) Receives a Buy From Mizuho Securities

TipRanksOct 14 03:00 ET

ADMA Biologics Analyst Ratings

BenzingaSep 20 11:11 ET

Cantor Fitzgerald Reiterates Overweight on ADMA Biologics, Maintains $20 Price Target

BenzingaSep 20 11:10 ET

Buy Rating Affirmed for ADMA Biologics Amid Strong Financial Performance and Promising R&D Prospects

TipRanksAug 12 06:30 ET

ADMA Biologics Price Target Raised to $20.00/Share From $15.00 by Cantor Fitzgerald

Dow JonesAug 9 11:36 ET

ADMA Biologics Analyst Ratings

BenzingaAug 9 11:27 ET

Analysts Offer Insights on Healthcare Companies: Paragon 28 (FNA), ADMA Biologics (ADMA) and Veracyte (VCYT)

TipRanksAug 9 08:48 ET

ADMA Biologics Analyst Ratings

BenzingaJul 9 09:24 ET

ADMA Biologics Analyst Ratings

BenzingaJun 20 08:15 ET

ADMA Biologics Analyst Ratings

BenzingaMay 10 08:01 ET